Ad-hoc: Marinomed Biotech AG has been a victim of cybercrime
Ad-hoc: Marinomed Biotech AG resolves second capital increase excluding statutory subscription rights by issuing 83,750 no-par value bearer shares at an issue price of EUR 8 per share
Ad-hoc: Marinomed Biotech AG: Binding Term Sheet for the intended issuance of a convertible bond to the European Investment Bank (EIB) signed
Ad-hoc: Marinomed Biotech AG: Publication of a report on the exclusion of subscription rights for a possible second cash capital increase of up to 154,053 shares
Lucia Ziegler, MSc
Head of Investor & Public Relations